Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89


CK8/18 expression, the basal phenotype, and family history in identifying BRCA1-associated breast cancer in the Ontario site of the breast cancer family registry.

Mulligan AM, Pinnaduwage D, Bane AL, Bull SB, O'Malley FP, Andrulis IL.

Cancer. 2011 Apr 1;117(7):1350-9. doi: 10.1002/cncr.25642. Epub 2010 Nov 2.


BRCA-mutated Invasive Breast Carcinomas: Immunohistochemical Analysis of Insulin-like Growth Factor II mRNA-binding Protein (IMP3), Cytokeratin 8/18, and Cytokeratin 14.

Mohanty SK, Lai JP, Gordon OK, Pradhan D, Bose S, Dadmanesh F.

Breast J. 2015 Nov-Dec;21(6):596-603. doi: 10.1111/tbj.12494. Epub 2015 Sep 22.


Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.

Collins LC, Martyniak A, Kandel MJ, Stadler ZK, Masciari S, Miron A, Richardson AL, Schnitt SJ, Garber JE.

Am J Surg Pathol. 2009 Jul;33(7):1093-7. doi: 10.1097/PAS.0b013e31819c1c93.


Comparative microRNA profiling of sporadic and BRCA1 associated basal-like breast cancers.

Yan M, Shield-Artin K, Byrne D, Deb S, Waddell N; kConFab Investigators, kConFab, Haviv I, Fox SB.

BMC Cancer. 2015 Jul 8;15:506. doi: 10.1186/s12885-015-1522-4.


HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry.

Quenneville LA, Phillips KA, Ozcelik H, Parkes RK, Knight JA, Goodwin PJ, Andrulis IL, O'Malley FP.

Cancer. 2002 Nov 15;95(10):2068-75.


Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes.

Stefansson OA, Jonasson JG, Johannsson OT, Olafsdottir K, Steinarsdottir M, Valgeirsdottir S, Eyfjord JE.

Breast Cancer Res. 2009;11(4):R47. doi: 10.1186/bcr2334. Epub 2009 Jul 9. Erratum in: Breast Cancer Res. 2009;11(5):404.


Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers.

Aaltonen K, Blomqvist C, Amini RM, Eerola H, Aittomäki K, Heikkilä P, Nevanlinna H.

Clin Cancer Res. 2008 Apr 1;14(7):1976-83. doi: 10.1158/1078-0432.CCR-07-4100.


EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry.

Bane AL, Mulligan AM, Pinnaduwage D, O'Malley FP, Andrulis IL.

Breast Cancer Res Treat. 2011 Jun;127(3):831-9. doi: 10.1007/s10549-011-1380-y. Epub 2011 Feb 15.


Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status.

Prat A, Cruz C, Hoadley KA, Díez O, Perou CM, Balmaña J.

Breast Cancer Res Treat. 2014 Aug;147(1):185-91. doi: 10.1007/s10549-014-3056-x. Epub 2014 Jul 22.


Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer.

Pinilla SM, Honrado E, Hardisson D, Benítez J, Palacios J.

Breast Cancer Res Treat. 2006 Sep;99(1):85-90. Epub 2006 Mar 16.


Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers.

Bane A, Viloria-Petit A, Pinnaduwage D, Mulligan AM, O'Malley FP, Andrulis IL.

Breast Cancer Res Treat. 2013 Jul;140(1):195-205. doi: 10.1007/s10549-013-2591-1. Epub 2013 Jun 28.


p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations.

Sensi E, Tancredi M, Aretini P, Cipollini G, Naccarato AG, Viacava P, Bevilacqua G, Caligo MA.

Breast Cancer Res Treat. 2003 Nov;82(1):1-9.


Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.

Foulkes WD, Stefansson IM, Chappuis PO, Bégin LR, Goffin JR, Wong N, Trudel M, Akslen LA.

J Natl Cancer Inst. 2003 Oct 1;95(19):1482-5.


Contribution of large genomic BRCA1 alterations to early-onset breast cancer selected for family history and tumour morphology: a report from The Breast Cancer Family Registry.

Smith LD, Tesoriero AA, Wong EM, Ramus SJ, O'Malley FP, Mulligan AM, Terry MB, Senie RT, Santella RM, John EM, Andrulis IL, Ozcelik H, Daly MB, Godwin AK, Buys SS, Fox S, Goldgar DE, Giles GG, Hopper JL, Southey MC.

Breast Cancer Res. 2011 Jan 31;13(1):R14. doi: 10.1186/bcr2822.


The basal phenotype of BRCA1-related breast cancer: past, present and future.

Tischkowitz MD, Foulkes WD.

Cell Cycle. 2006 May;5(9):963-7. Epub 2006 May 1. Review.


Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.

Lee DS, Yoon SY, Looi LM, Kang P, Kang IN, Sivanandan K, Ariffin H, Thong MK, Chin KF, Mohd Taib NA, Yip CH, Teo SH.

Breast Cancer Res. 2012 Apr 16;14(2):R66.


Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.

Aloraifi F, Alshehhi M, McDevitt T, Cody N, Meany M, O'Doherty A, Quinn CM, Green AJ, Bracken A, Geraghty JG.

Eur J Surg Oncol. 2015 May;41(5):641-6. doi: 10.1016/j.ejso.2015.01.021. Epub 2015 Feb 17.


Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.

Palacios J, Honrado E, Osorio A, Cazorla A, Sarrió D, Barroso A, Rodríguez S, Cigudosa JC, Diez O, Alonso C, Lerma E, Sánchez L, Rivas C, Benítez J.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3606-14.


Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors.

Laakso M, Loman N, Borg A, Isola J.

Mod Pathol. 2005 Oct;18(10):1321-8.


Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas.

Rodríguez-Pinilla SM, Sarrió D, Honrado E, Moreno-Bueno G, Hardisson D, Calero F, Benítez J, Palacios J.

J Clin Pathol. 2007 Sep;60(9):1006-12. Epub 2006 Nov 14.

Supplemental Content

Support Center